Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

Researchers have mapped the genetic landscape of cancer drug resistance, uncovering that DNA changes can be grouped into four main categories and highlighting possible new therapeutic targets.

Northwestern Medicine scientists have discovered how a protein in a deadly type of lung cancer can control how the immune ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial.

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) traded higher on Tuesday after the company said a Phase 3 trial designed to test its lung ...

Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...

Antibody-drug conjugates (ADCs) combine antibodies with cytotoxic drugs to target cancer cells while minimizing damage to ...

Dizal and Burning Rock’s NGS-based companion diagnostic for lung cancer receives China NMPA marketing nod: Shanghai, China Monday, October 14, 2024, 16:00 Hrs [IST] Dizal, a bio ...

There are no approved therapies to tackle c-Met protein overexpression, AbbVie said in a press release. C-Met is a receptor ...

In a breakthrough for cancer research, Medgnosis has leveraged its state-of-the-art generative AI (GenAI) system to transform drug discovery. This GenAI targets both druggable and undruggable proteins ...

Hilmar Warenius on how his discovery of a new type of cancer treatment could be well on its way to revolutionising the ...